Loading the comparison…
Loading the comparison…
Growth Hormone Axis
The classic GH-stimulating pair in one vial.
Growth Hormone Axis
A long-acting lab version of IGF-1, the hormone growth hormone works through.
CJC-1295 (no DAC) + Ipamorelin is not FDA-approved and rated 3/5 for evidence; IGF-1 LR3 is not FDA-approved and rated 1/5. CJC-1295 (no DAC) + Ipamorelin has more human evidence behind it. Both are banned in sport by WADA. Both are used for growth hormone axis goals.
| Compare | CJC-1295 (no DAC) + Ipamorelin The classic GH-stimulating pair in one vial. | IGF-1 LR3 A long-acting lab version of IGF-1, the hormone growth hormone works through. |
|---|---|---|
| Category | Growth Hormone Axis | Growth Hormone Axis |
| Evidence | 3/5Each component studied in humans for GH release; the combined long-term outcomes data is thin. | 1/5Developed as a cell-culture reagent. No human clinical trials of LR3. Human data exists only for the approved native IGF-1 drug (mecasermin), a different product. |
| FDA status | Not FDA-approved | Not FDA-approved |
| WADA (sport) | Banned | Banned |
| Also known as | Modified GRF 1-29 + Ipamorelin, CJC/Ipa blend | Long R3 IGF-1, Long Arg3 IGF-1, LR3-IGF-1 |
| How it works | Two receptors, one pulse: GHRH-receptor stimulation (CJC-1295) plus ghrelin-receptor stimulation (ipamorelin) produces a larger-than-either GH release. Short half-life keeps the pulsatile pattern. | Activates the IGF-1 receptor, which drives cell growth, protein building and glucose uptake. Because it largely escapes IGF-binding proteins, more of it stays free and active than with native IGF-1. |
| Half-life | CJC no-DAC ≈ 30 min; ipamorelin ≈ 2 h | Longer than native IGF-1 (often quoted as about 20–30 hours); not well studied in humans |
| Commonly reported doses |
|
|
| Route | Subcutaneous | Subcutaneous or intramuscular |
| Good once mixed | ~21 days in the fridge | ~21 days in the fridge |
| Top side effects |
|
|
| Lowest research-listing price per mg | $3.60 (10 mg vial, 40% off) | $41.99 (1 mg vial, 40% off) |
| Latest lab purity | 99.12% (lot CIP0003) | 99.03% (lot IGF0002) |
Want a third? Add another peptide. Doses are commonly reported ranges, not recommendations.
Free for ChatGPT and Claude
Connect MyPeps to ChatGPT or Claude and ask follow-ups about CJC-1295 (no DAC) + Ipamorelin and IGF-1 LR3. It answers from these same pages, with links back here.
CJC-1295 (no DAC) + Ipamorelin is not FDA-approved and rated 3/5 for evidence; IGF-1 LR3 is not FDA-approved and rated 1/5. CJC-1295 (no DAC) + Ipamorelin has more human evidence behind it. Both are banned in sport by WADA. Both are used for growth hormone axis goals.
CJC-1295 (no DAC) + Ipamorelin: Not FDA-approved. IGF-1 LR3: Not FDA-approved. Regulations change, so confirm with the FDA.
CJC-1295 (no DAC) + Ipamorelin is rated 3 out of 5: Each component studied in humans for GH release; the combined long-term outcomes data is thin. IGF-1 LR3 is rated 1 out of 5: Developed as a cell-culture reagent. No human clinical trials of LR3. Human data exists only for the approved native IGF-1 drug (mecasermin), a different product. The scale is explained on our methodology page.
CJC-1295 (no DAC) + Ipamorelin is banned by WADA, by name or as part of a named class. IGF-1 LR3 is banned by WADA, by name or as part of a named class.